Last edition
News about "Relapsed or Refractory Multiple Myeloma"
BMS Reports Positive EXCALIBER-RRMM Results for Zenbexus in Multiple Myeloma
Bristol Myers Squibb reported phase 3 EXCALIBER-RRMM results showing higher MRD-negative complete response rates with Zenbexus plus daratumumab and dexamethasone.
Relapsed Or Refractory Multiple Myeloma | 28/09/2026 | By News Bureau | 151
Pathos AI, AstraZeneca Partner to Advance AI-Driven Breast Cancer Therapy into Clinical Development
Pathos AI and AstraZeneca have entered a strategic collaboration to advance AZD4241, an investigational therapy for ER+/HER2- breast cancer, using artificial intelligence to enhance clinical development and precision oncology.
Relapsed Or Refractory Multiple Myeloma | 05/08/2026 | By News Bureau | 200
Bristol Myers Squibb reported Phase 3 SUCCESSOR-2 results showing that mezigdomide reduced the risk of disease progression or death by more than 50% versus standard of care in relapsed or refractory multiple myeloma, marking the first successful Phase 3 CELMoD trial presented at ASCO 2026.
Relapsed Or Refractory Multiple Myeloma | 30/05/2026 | By News Bureau | 184
U.S. Food and Drug Administration grants rapid approval to Tec-Dara, a combination of teclistamab and daratumumab hyaluronidase-fihj, for adults with relapsed or refractory multiple myeloma after at least one prior therapy.
Relapsed Or Refractory Multiple Myeloma | 07/03/2026 | By News Bureau | 193
Iberdomide, an investigational oral CELMoD therapy, is under FDA review in combination with daratumumab and dexamethasone for patients with relapsed or refractory multiple myeloma.
Relapsed Or Refractory Multiple Myeloma | 19/02/2026 | By News Bureau | 249
Innovent Biologics’ tri-specific antibody IBI3003 has received FDA Fast Track Designation for heavily pretreated relapsed or refractory multiple myeloma, supported by promising early clinical efficacy and safety data.
Relapsed Or Refractory Multiple Myeloma | 27/01/2026 | By News Bureau | 359
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy